Klein, Pavel; Kaminski, Rafal M; Koepp, Matthias; Löscher, Wolfgang; (2024) New epilepsy therapies in development. Nature Reviews Drug Discovery , 23 pp. 682-708. 10.1038/s41573-024-00981-w.

Preview	Text Koepp_Klein_v4_edit KK_for accept.pk.5.21.24.pdf - Accepted Version Download (812kB) | Preview
Preview	Text Koepp_NRDD-23-167 Klein-Figure proof v2_WL.pdf - Accepted Version Download (1MB) | Preview

Abstract

Epilepsy is a common brain disorder, characterized by spontaneous recurrent seizures, with associated neuropsychiatric and cognitive comorbidities and increased mortality. Although people at risk can often be identified, interventions to prevent the development of the disorder are not available. Moreover, in at least 30% of patients, epilepsy cannot be controlled by current antiseizure medications (ASMs). As a result of considerable progress in epilepsy genetics and the development of novel disease models, drug screening technologies and innovative therapeutic modalities over the past 10 years, more than 200 novel epilepsy therapies are currently in the preclinical or clinical pipeline, including many treatments that act by new mechanisms. Assisted by diagnostic and predictive biomarkers, the treatment of epilepsy is undergoing paradigm shifts from symptom-only ASMs to disease prevention, and from broad trial-and-error treatments for seizures in general to mechanism-based treatments for specific epilepsy syndromes. In this Review, we assess recent progress in ASM development and outline future directions for the development of new therapies for the treatment and prevention of epilepsy.

Download activity - last month

Export as XMLCSVJSON

Download activity - last 12 months

Export as CSVXMLJSON

Downloads by country - last 12 months

Export as CSVXMLJSON

Archive Staff Only

View Item